ENB 104
Alternative Names: ENB-104Latest Information Update: 26 Aug 2024
At a glance
- Originator EnnovaBio
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Diabetic nephropathies; Inflammatory bowel diseases; Peripheral T-cell lymphoma
Most Recent Events
- 31 Jul 2024 Phase-I clinical trials in Diabetic nephropathies (PO) prior to July 2024 (EnnovaBio pipeline, July 2024)
- 31 Jul 2024 Phase-I clinical trials in Inflammatory bowel diseases (PO) prior to July 2024 (EnnovaBio pipeline, July 2024)
- 31 Jul 2024 Phase-I clinical trials in Peripheral T-cell lymphoma (PO) prior to July 2024 (EnnovaBio pipeline, July 2024)